SELLAS Life Sciences (SLS) Cash from Financing Activities (2010 - 2026)
SELLAS Life Sciences (SLS) reported Cash from Financing Activities of $44.2 million for Q1 2026, up 87.23% year-over-year from $23.6 million in Q1 2025, and up 36.29% on a QoQ basis from $32.4 million in Q4 2025.
SELLAS Life Sciences (SLS) has 17 years of Cash from Financing Activities data on file, last reported at $44.2 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 87.23% year-over-year to $44.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $106.9 million (up 144.58% YoY) and the FY2025 annual result came in at $86.3 million, up 84.56% from the prior year.
- Cash from Financing Activities improved to $44.2 million in Q1 2026 per SLS's latest filing, from $32.4 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $44.2 million in Q1 2026 and bottomed at -$29000.0 in Q2 2023.
- The 5-year median for Cash from Financing Activities is $4.2 million (2025), against an average of $13.2 million.
- The widest annual swing landed in 2023, when Cash from Financing Activities sank 100.13%; it then jumped 404825.0% in 2025.
- Tracing SLS's Cash from Financing Activities over 5 years: stood at $929000.0 in 2022, then soared by 264.48% to $3.4 million in 2023, then sank by 99.76% to $8000.0 in 2024, then jumped by 404825.0% to $32.4 million in 2025, then surged by 36.29% to $44.2 million in 2026.
- Per Business Quant, the three latest SLS Cash from Financing Activities figures stand at $44.2 million (Q1 2026), $32.4 million (Q4 2025), and $26.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 15.71 Mn |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - | 44.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 44.15 Mn |
| Mar 31, 2026 | 44.15 Mn |
| Dec 31, 2025 | 32.39 Mn |
| Dec 31, 2025 | 32.39 Mn |
| Sep 30, 2025 | 26.09 Mn |
| Sep 30, 2025 | 26.09 Mn |
| Jun 30, 2025 | 4.23 Mn |
| Jun 30, 2025 | 4.23 Mn |
| Mar 31, 2025 | 23.58 Mn |
| Mar 31, 2025 | 23.58 Mn |
| Dec 31, 2024 | 8,000.00 |
| Dec 31, 2024 | 8,000.00 |
| Sep 30, 2024 | 19.69 Mn |
| Sep 30, 2024 | 19.69 Mn |
| Jun 30, 2024 | 414,000.00 |
| Jun 30, 2024 | 414,000.00 |
| Mar 31, 2024 | 26.65 Mn |
| Mar 31, 2024 | 26.65 Mn |
| Dec 31, 2023 | 3.39 Mn |
| Dec 31, 2023 | 3.39 Mn |
| Sep 30, 2023 | 54,000.00 |
| Sep 30, 2023 | 54,000.00 |
| Jun 30, 2023 | -29,000.00 |
| Jun 30, 2023 | -29,000.00 |
| Mar 31, 2023 | 18.90 Mn |
| Mar 31, 2023 | 18.90 Mn |
| Dec 31, 2022 | 929,000.00 |
| Dec 31, 2022 | 929,000.00 |
| Sep 30, 2022 | 107,000.00 |
| Sep 30, 2022 | 107,000.00 |
| Jun 30, 2022 | 23.00 Mn |
| Jun 30, 2022 | 23.00 Mn |
| Mar 31, 2022 | 47,000.00 |
| Mar 31, 2022 | 47,000.00 |
| Dec 31, 2021 | 50,000.00 |
| Dec 31, 2021 | 50,000.00 |
| Sep 30, 2021 | 2.24 Mn |
| Sep 30, 2021 | 2.24 Mn |
| Jun 30, 2021 | 6.78 Mn |
| Jun 30, 2021 | 6.78 Mn |
| Mar 31, 2021 | 3.00 Mn |
| Mar 31, 2021 | 3.00 Mn |
| Dec 31, 2020 | 23.68 Mn |
| Dec 31, 2020 | 23.68 Mn |
| Sep 30, 2020 | 8.49 Mn |
| Sep 30, 2020 | 8.49 Mn |
| Jun 30, 2020 | -25,000.00 |
| Jun 30, 2020 | -25,000.00 |
| Mar 31, 2020 | 6.30 Mn |
| Mar 31, 2020 | 6.30 Mn |
| Dec 31, 2019 | 2.32 Mn |
| Dec 31, 2019 | 2.32 Mn |
| Sep 30, 2019 | 189,000.00 |
| Sep 30, 2019 | 189,000.00 |
| Jun 30, 2019 | 14.83 Mn |
| Jun 30, 2019 | 14.83 Mn |
| Mar 31, 2019 | 2.23 Mn |
| Mar 31, 2019 | 2.23 Mn |
| Dec 31, 2018 | -76,000.00 |
| Dec 31, 2018 | -76,000.00 |
| Sep 30, 2018 | 14.25 Mn |
| Sep 30, 2018 | 14.25 Mn |
| Jun 30, 2018 | 4.21 Mn |
| Jun 30, 2018 | 4.21 Mn |
| Mar 31, 2018 | 4.74 Mn |
| Mar 31, 2018 | 4.74 Mn |
| Dec 31, 2017 | -120,000.00 |
| Dec 31, 2017 | -120,000.00 |
| Sep 30, 2017 | -1,000.00 |
| Sep 30, 2017 | -1,000.00 |
| Jun 30, 2017 | 5.66 Mn |
| Jun 30, 2017 | 5.66 Mn |
| Dec 31, 2016 | -16.26 Mn |
| Dec 31, 2016 | -16.26 Mn |
| Sep 30, 2016 | 17.13 Mn |
| Sep 30, 2016 | 17.13 Mn |
| Jun 30, 2016 | -3.63 Mn |
| Jun 30, 2016 | -3.63 Mn |
| Mar 31, 2016 | 19.25 Mn |
| Mar 31, 2016 | 19.25 Mn |
| Dec 31, 2015 | -1.01 Mn |
| Dec 31, 2015 | -1.01 Mn |
| Sep 30, 2015 | -759,000.00 |
| Sep 30, 2015 | -759,000.00 |
| Jun 30, 2015 | 4.33 Mn |
| Jun 30, 2015 | 4.33 Mn |
| Mar 31, 2015 | 41.28 Mn |
| Mar 31, 2015 | 41.28 Mn |
| Dec 31, 2014 | 9.85 Mn |
| Dec 31, 2014 | 9.85 Mn |
| Sep 30, 2014 | -325,000.00 |
| Sep 30, 2014 | -325,000.00 |
| Jun 30, 2014 | 19,000.00 |
| Jun 30, 2014 | 19,000.00 |
| Mar 31, 2014 | 14.72 Mn |
| Mar 31, 2014 | 14.72 Mn |
| Dec 31, 2013 | 7.69 Mn |
| Dec 31, 2013 | 7.69 Mn |
| Sep 30, 2013 | 37.74 Mn |
| Sep 30, 2013 | 37.74 Mn |
| Jun 30, 2013 | 10.43 Mn |
| Jun 30, 2013 | 10.43 Mn |
| Mar 31, 2013 | 92,000.00 |
| Mar 31, 2013 | 92,000.00 |
| Dec 31, 2012 | 22.56 Mn |
| Dec 31, 2012 | 22.56 Mn |
| Sep 30, 2012 | 360,000.00 |
| Sep 30, 2012 | 360,000.00 |
| Jun 30, 2012 | 17.36 Mn |
| Jun 30, 2012 | 17.36 Mn |
| Mar 31, 2012 | 2.15 Mn |
| Mar 31, 2012 | 2.15 Mn |
| Dec 31, 2011 | 10,000.00 |
| Dec 31, 2011 | 10,000.00 |
| Sep 30, 2011 | 1.17 Mn |
| Sep 30, 2011 | 1.17 Mn |
| Jun 30, 2011 | 10.72 Mn |
| Jun 30, 2011 | 10.72 Mn |
| Mar 31, 2011 | 7.29 Mn |
| Mar 31, 2011 | 7.29 Mn |
| Dec 31, 2010 | -25,000.00 |
| Dec 31, 2010 | -25,000.00 |
| Sep 30, 2010 | -15,000.00 |
| Sep 30, 2010 | -15,000.00 |